ArriVent BioPharma, Inc.

The company is a clinical-stage biopharmaceutical company that identifies, develops, and commercializes differentiated cancer therapies, with a primary focus on solid tumors. Its lead product candidate is firmonertinib, an investigational tyrosine kinase inhibitor evaluated in clinical trials for non-small cell lung cancer characterized by epidermal growth factor receptor mutations, notably exon 20 insertions and PACC mutations. In addition, the firm is developing a pipeline of novel therapeutics, including next-generation antibody drug conjugates such as ARR-217 for gastrointestinal cancers and other solid tumors. Its prospective customers and end users are cancer patients with underserved oncological conditions.

The company operates globally through collaborative clinical development programs across regions including the United States, Europe, and Asia. It sources therapeutic candidates worldwide—frequently initiating partnerships in China—and conducts international multi-center clinical trials, with commercial rights spanning territories outside greater China. Its corporate headquarters is not stated in the provided text.

Summary of the business section of ArriVent BioPharma's latest annual report, written by StockData.

“As of December 31, 2025, we had 77 employees, all of whom were full-time and 45 of whom were engaged in research and development activities.”